Lead candidate in the MLLT1/3 programme, DBT 3757, is a differentiated investigational molecule designed to treat Acute Myeloid LeukemiaAcquisition brings a new therapeutic mechanism to Amgen's ...
Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia THOUSAND OAKS, Calif., Jan. 6, 2026 /PRNewswire/ -- Amgen (NASDAQ: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback